Rocket Pharmaceuticals, Inc. Common Stock

RCKTNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
2.75 USD
↘ 0.17 (5.82%)AT CLOSE (11:59 AM EDT)
2.78
↗ 0.03 (1.24%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
2.78
↗ 0.03 (1.24%)
🔴Market: CLOSED
Open?$2.90
High?$2.92
Low?$2.69
Prev. Close?$2.92
Volume?2.6M
Avg. Volume?2.3M
VWAP?$2.75
Rel. Volume?1.10x
Bid / Ask
Bid?$2.70 × 200
Ask?$2.79 × 1.8K
Spread?$0.09
Midpoint?$2.75
Valuation & Ratios
Market Cap?300.3M
Shares Out?109.2M
Float?84.0M
Float %?77.0%
P/E Ratio?N/A
P/B Ratio?1.26
EPS?-$1.92
Dividend?0.00%
Ex-Dividend?N/A

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $2.75 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
202
Market Cap
300.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.rocketpharma.com
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.47Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.93%Squeeze Risk
Short Interest?20.9M
Days to Cover?10.1
Free Float84.0M
Avg Daily Volume2.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?6.12Strong
Quick Ratio?6.12Strong
Cash Ratio?2.03Strong
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
92
1.26CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-88.0%WEAK▾
ROA?
S&P
3
-73.4%WEAK▾
Cash Flow & Enterprise
FCF?$-179787000
Enterprise Value?$271.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist